Cargando…
Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
The Janus kinases (JAKs) are intracellular tyrosine kinases involved in a broad variety of inflammatory cascades participating in the pathogenesis of systemic lupus erythematosus (SLE). Diffuse non-scarring alopecia is one of the most frequent cutaneous manifestations in SLE, resulting in devastatin...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080875/ https://www.ncbi.nlm.nih.gov/pubmed/33936080 http://dx.doi.org/10.3389/fimmu.2021.654376 |
_version_ | 1783685529253969920 |
---|---|
author | Chen, Yu-Lan Liu, Li-Xiong Huang, Qin Li, Xue-Ying Hong, Xiao-Ping Liu, Dong-Zhou |
author_facet | Chen, Yu-Lan Liu, Li-Xiong Huang, Qin Li, Xue-Ying Hong, Xiao-Ping Liu, Dong-Zhou |
author_sort | Chen, Yu-Lan |
collection | PubMed |
description | The Janus kinases (JAKs) are intracellular tyrosine kinases involved in a broad variety of inflammatory cascades participating in the pathogenesis of systemic lupus erythematosus (SLE). Diffuse non-scarring alopecia is one of the most frequent cutaneous manifestations in SLE, resulting in devastating psychosocial consequences. Although recent studies have shown promising outcomes of the JAK inhibitors in SLE treatment, the efficacy of tofacitinib in diffuse non-scarring alopecia due to SLE has never been reported. Here we present a 29-year-old SLE patient with a 10-year history of refractory severe diffuse non-scarring alopecia who experienced dramatic hair regrowth with tofacitinib. Furthermore, we have made a systematic review regarding the potential effectiveness of tofacitinib in systemic and cutaneous lupus erythematosus. To the best of our knowledge, this is the first case study depicting an SLE patient with refractory alopecia who experienced impressive hair regrowth with the JAK1/3 inhibitor tofacitinib therapy, which contributes to expanding the field of possible uses of tofacitinib in SLE patients with difficult-to-treat cutaneous involvement, including severe alopecia. |
format | Online Article Text |
id | pubmed-8080875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80808752021-04-29 Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib Chen, Yu-Lan Liu, Li-Xiong Huang, Qin Li, Xue-Ying Hong, Xiao-Ping Liu, Dong-Zhou Front Immunol Immunology The Janus kinases (JAKs) are intracellular tyrosine kinases involved in a broad variety of inflammatory cascades participating in the pathogenesis of systemic lupus erythematosus (SLE). Diffuse non-scarring alopecia is one of the most frequent cutaneous manifestations in SLE, resulting in devastating psychosocial consequences. Although recent studies have shown promising outcomes of the JAK inhibitors in SLE treatment, the efficacy of tofacitinib in diffuse non-scarring alopecia due to SLE has never been reported. Here we present a 29-year-old SLE patient with a 10-year history of refractory severe diffuse non-scarring alopecia who experienced dramatic hair regrowth with tofacitinib. Furthermore, we have made a systematic review regarding the potential effectiveness of tofacitinib in systemic and cutaneous lupus erythematosus. To the best of our knowledge, this is the first case study depicting an SLE patient with refractory alopecia who experienced impressive hair regrowth with the JAK1/3 inhibitor tofacitinib therapy, which contributes to expanding the field of possible uses of tofacitinib in SLE patients with difficult-to-treat cutaneous involvement, including severe alopecia. Frontiers Media S.A. 2021-04-14 /pmc/articles/PMC8080875/ /pubmed/33936080 http://dx.doi.org/10.3389/fimmu.2021.654376 Text en Copyright © 2021 Chen, Liu, Huang, Li, Hong and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Chen, Yu-Lan Liu, Li-Xiong Huang, Qin Li, Xue-Ying Hong, Xiao-Ping Liu, Dong-Zhou Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib |
title | Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib |
title_full | Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib |
title_fullStr | Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib |
title_full_unstemmed | Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib |
title_short | Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib |
title_sort | case report: reversal of long-standing refractory diffuse non-scarring alopecia due to systemic lupus erythematosus following treatment with tofacitinib |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080875/ https://www.ncbi.nlm.nih.gov/pubmed/33936080 http://dx.doi.org/10.3389/fimmu.2021.654376 |
work_keys_str_mv | AT chenyulan casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib AT liulixiong casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib AT huangqin casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib AT lixueying casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib AT hongxiaoping casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib AT liudongzhou casereportreversaloflongstandingrefractorydiffusenonscarringalopeciaduetosystemiclupuserythematosusfollowingtreatmentwithtofacitinib |